Biosimilar Pharmaceuticals
"Biosimilar Pharmaceuticals" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
BIOLOGIC PRODUCTS that are imitations but not exact replicas of innovator products.
| Descriptor ID |
D059451
|
| MeSH Number(s) |
D20.215.261
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Biosimilar Pharmaceuticals".
Below are MeSH descriptors whose meaning is more specific than "Biosimilar Pharmaceuticals".
This graph shows the total number of publications written about "Biosimilar Pharmaceuticals" by people in this website by year, and whether "Biosimilar Pharmaceuticals" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
| 2022 | 1 | 0 | 1 |
| 2023 | 3 | 0 | 3 |
| 2024 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Biosimilar Pharmaceuticals" by people in Profiles.
-
Public deliberation to assess patient views on biosimilar medication switching for the treatment of inflammatory bowel disease. BMC Health Serv Res. 2024 Oct 09; 24(1):1209.
-
A narrative review of the comparative safety of disease-modifying anti-rheumatic drugs used for the treatment of rheumatoid arthritis. Expert Opin Drug Saf. 2024 Jun; 23(6):687-714.
-
Production of a biosimilar version of aflibercept to improve VEGF blocker cytotoxicity on endothelial cells. Growth Factors. 2023 08; 41(3):140-151.
-
Systematic review of efficacy and meta-analysis of safety of ranibizumab biosimilars relative to reference ranibizumab anti-VEGF therapy for nAMD treatment. BMJ Open Ophthalmol. 2023 06; 8(1).
-
Safety of recent ophthalmic drugs and devices for wet macular degeneration. Curr Opin Ophthalmol. 2023 Sep 01; 34(5):363-368.
-
Re: Lin I, Melsheimer R, Bhak RH, et al. Impact of switching to infliximab biosimilars on treatment patterns among US veterans receiving innovator infliximab. Curr Med Res Opin. 2022;38(4):613-627. Curr Med Res Opin. 2022 12; 38(12):2241-2242.
-
Factors Influencing Infusion-Related Reactions Following Dosing of Reference Rituximab and PF-05280586, a Rituximab Biosimilar. BioDrugs. 2021 Jul; 35(4):459-468.
-
Treatment of infections in cancer patients: an update from the neutropenia, infection and myelosuppression study group of the Multinational Association for Supportive Care in Cancer (MASCC). Expert Rev Clin Pharmacol. 2021 Mar; 14(3):295-313.
-
Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021 03 02; 19(3):329-359.
-
Coverage for Biosimilars vs Reference Products Among US Commercial Health Plans. JAMA. 2020 05 19; 323(19):1972-1973.